✦ LIBER ✦

PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL AND PEMETREXED FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN TAIWAN

✍ Scribed by TC Hsia; GC Chang; YM Chen; MC Lin; WC Su; CM Tsai; CM Tsai; L Yang; J Creeden

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN90 Cost-Effectiveness Analysis of Erl

✍ Nguyen, T.T.T.; Yagudina, R.; Kulikov, A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PCN10 COSTS OF MANAGING TOXICITIES IN AD

✍ M Aristides; D Jackson; AM Liepa; NB Leighl; F Shepherd 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

PCN77 PHARMACOECONOMIC ANALYSIS OF ERLOT

✍ O Batigun; E Yildirim 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

PCN36 ECONOMIC EVALUATION OF ERLOTINIB,

✍ S Capri; A Morabito; G Carillio; F Grossi; R Longo; G Cerea; F Rossetti 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

PCN120 COST-UTILITY OF DOCETAXEL COMPARE

✍ J Rutkowski; B Gwiosda; B Lisiecka; M Wladysiuk; J Lis; R Plisko; P Rys 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

PCN50 COST-MINIMIZATION ANALYSIS OF ERLO

✍ E Suchankova; T Doležal 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB